ライノウイルス用ワクチンの世界市場

VacZine Analyticsが発行した調査報告書(VACZ712007)
◆英語タイトル:MarketVIEW: Rhinovirus vaccines
◆商品コード:VACZ712007
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2017年5月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF、Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Executive Presentation (PDF)USD6,156 ⇒換算¥695,628見積依頼/購入/質問フォーム
PDF+ExcelUSD8,795 ⇒換算¥993,835見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Human rhinovirus (HRV) is the major causes of the common cold. It can cause of morbidity in patients with chronic respiratory diseases, as well as infants and the elderly. In individuals with asthma, COPD and cystic fibrosis, HRV is associated with acute exacerbations that generate high healthcare costs largely due to hospitalizations. HRV also causes bronchiolitis in infants and respiratory illness in older adults. The treatment of HRV infection is primarily supportive, including over-the-counter products aimed at symptom relief.
A broadly-protective HRV vaccine may have a significant public health impact if it could reduce or prevention of exacerbations in COPD and asthma patients. This should result in significant healthcare cost savings as hospitalization is a key direct cost during an episode. There are currently no HRV vaccines in active clinical development. Preclinical activity is ongoing.

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Rhinovirus vaccines across Western markets to 2030. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.

【レポートの目次】

Title page
Contents
Author’s note
Executive summary
HRV vaccines commercial model: key outputs
HRV vaccines: potential value ($m) by low/base/high price to 2030
HRV vaccines: potential value ($m) by target population (base price) to 2030
HRV vaccines: potential value ($m) by region (base price) to 2030
HRV: background and epidemiology
Human rhinovirus: overview
HRV – genotypes
HRV – transmission, pathogenesis and host response1
Epidemiology: HRV disease burden
Epidemiology: data – England 2009-2012
Disease burden caused by common respiratory viruses
HRV disease burden: adults
HRV disease burden: respiratory viral infections and hospitalization
HRV disease burden: adults – summary
HRV disease burden: infants
Human rhinovirus: risk factors for severe infant infection
HRV disease burden: infants – summary
HRV disease burden: elderly
HRV disease burden: elderly – comparative to other viruses
HRV – mortality of hospitalised elderly patients versus flu
HRV disease burden: elderly – COPD
HRV disease burden: elderly – risk groups
HRV disease burden: asthma exacerbations
HRV disease burden: asthma exacerbations – association
HRV disease burden: asthma exacerbations – therapies
HRV disease burden: asthma exacerbations & HRV vaccine
HRV disease burden: asthma exacerbations – unmet need
HRV – a cause of childhood asthma?
HRV disease burden: COPD exacerbations
HRV disease burden: COPD exacerbations & viral infection
HRV disease burden: COPD exacerbations & disease severity
HRV disease burden: COPD exacerbations & related costs
HRV disease burden: COPD exacerbations & treatments
1 Model contents available upon application 2 Presentation titles may apply to more than one slide

HRV disease burden: COPD exacerbations & economics
HRV disease burden: COPD exacerbations & HRV vaccine
HRV - other risk groups (HSCTs)
HRV vaccines – R&D pipeline
ViravaxX - HRV vaccine
A putative HRV vaccine: commercial model assumptions
The role of an HRV vaccine
HRV vaccine target product profile (TPP)
HRV vaccine: points to note
Main target markets for HRV vaccines
Commercial model: major inputs
Drivers and resistors for a successful HRV vaccine
Commercial parameters of respiratory viruses vaccines
Back-up: methodology
Methodology: populations (COPD)
Methodology: populations – COPD per country
Methodology: populations – asthma
Methodology: populations – asthma prevalence
Methodology: vaccine uptake
About VacZine Analytics
Disclaimer
Slide number = 77

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ライノウイルス用ワクチンの世界市場(MarketVIEW: Rhinovirus vaccines)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆